IPO Launch: Aligos Therapeutics Readies $150 Million U.S. IPO
IPOStreet
16 hours ago
Aligos Therapeutics (ALGS) intends to raise $150 million in an IPO of its common stock, according to an S-1 registration statement.
South San Francisco, California-based Aligos was founded to develop a functional cure for Hepatitis B and other liver and viral diseases.
Management is headed by co-founder and CEO Mr. Lawrence Blatt, Ph.D., who was previously Global Head of Infectious Diseases and Vaccines at Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson (JNJ).
IPO发行：Aligos Therapeutics准备在美国进行1.5亿美元的IPO